Literature DB >> 6394514

Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial.

U Lepola, S Kokko, J Nuutila, A Gordin.   

Abstract

The efficacy of chlordiazepoxide and tiapride in the management of acute alcohol withdrawal syndrome was compared in a randomized, parallel-group, double-blind trial. The mean daily dose for both preparations on the first two days was four capsules, i.e., 200 mg for chlordiazepoxide and 400 mg for tiapride. Thereafter the patients were treated according to the relief of symptoms obtained. The treatment periods lasted 3-5 days. Both drugs effectively alleviated alcohol withdrawal symptoms, especially anxiety, fear, hallucinations, insomnia, sweating, tremor, abdominal pain and vertigo. Seventy percent of the patients in the chlordiazepoxide and 42% in the tiapride group considered the drug effective. The difference was statistically significant in favour of chlordiazepoxide (p less than 0.05). Tiapride is an alternative drug in the treatment of this condition, if benzodiazepines are to be avoided.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6394514

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  3 in total

1.  Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients.

Authors:  Michael Soyka; Peggy Schmidt; Michael Franz; Thomas Barth; Michael de Groot; Thorsten Kienast; Thomas Reinert; Christoph Richter; Greif Sander
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-17       Impact factor: 5.270

2.  [Carbamazepine intoxication. Complication of alcohol detoxification with combined carbamazepine and tiapride].

Authors:  A Diehl; M Grosshans; H Herre; B Croissant; K Mann
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 3.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.